Aarti Pharmalabs Ltd. (AARTIPHARM) fundamentals
Aarti Pharmalabs Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as AARTIPHARM (ISIN INE0LRU01027). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Aarti Pharmalabs Ltd. does
Aarti Pharmalabs Limited is engaged in the manufacturing of active pharmaceutical ingredients (APIs), advanced intermediates, and xanthine derivatives, based in India. The Company also offers comprehensive contract development and manufacturing organization (CDMO) and CMO services for drug substances and new chemical entities (NCE), including their key starting materials (KSM) and regulatory starting materials (RSM), serving various pharmaceutical companies worldwide with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of HPAPIs, corticosteroids, cytotoxic medicines, and oncology products. Its caffeine products include caffeine anhydrous, and caffeine anhydrous (granules). Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its products are exported to key regulated markets such as the United States (US), the European Union, and Japan.
Valuation and market data
| Last close | ₹825.75 |
|---|---|
| Market capitalisation | ₹7,483 crore |
| Enterprise value | ₹7,736 crore |
| P/E (TTM) | 0.00 |
| Price to book | 3.76 |
| Price to sales (TTM) | 3.78 |
| Book value per share | ₹219.59 |
| Dividend yield | 48.44% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Jan 30 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,813 crore | ₹234 crore | ₹176 crore | 0.00 |
| Mar 2025 | ₹1,786 crore | ₹336 crore | ₹257 crore | 28.39 |
| Mar 2024 | ₹1,513 crore | ₹275 crore | ₹201 crore | 22.14 |
| Mar 2023 | ₹1,513 crore | ₹233 crore | ₹172 crore | 18.95 |
| Mar 2022 | ₹944 crore | ₹134 crore | ₹107 crore | 11.78 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 42.9% |
|---|---|
| Foreign institutions (FII) | 8.2% |
| Mutual funds | 0.8% |
| Other domestic institutions | 6.4% |
| Retail and others | 41.7% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.